Therapeutic Targets of the TNF Superfamily
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | eBook |
| Lenguaje: | English |
| Publicado: |
New York, NY :
Springer New York : Imprint: Springer,
2009.
|
| Edición: | 1st ed. 2009. |
| Colección: | Advances in Experimental Medicine and Biology,
647 |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/978-0-387-89520-8 |
Tabla de Contenidos:
- Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets
- Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges
- Targeting TNF for Treatment of Cancer and Autoimmunity
- Targeting of BAFF and APRIL for Autoimmunity and Oncology
- The Role of FasL and Fas in Health and Disease
- OX40 (CD134) and OX40L
- Targeting CD70 for Human Therapeutic Use
- 4-1BB as a Therapeutic Target for Human Disease
- RANK(L) as a Key Target for Controlling Bone Loss
- Targeting the LIGHT-HVEM Pathway
- GITR: A Modulator of Immune Response and Inflammation
- Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases
- Tumor Necrosis Factor Receptor Superfamily Member 21: TNFR-Related Death Receptor-6, DR6
- TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics
- Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer.